With a threefold increase in recurrence rates in patients with cellular senescence‐related p53/p14 double‐positive breast cancer compared with that in p53/p14 double‐negative patients, a fourfold increase in the recurrence rates in patients with P53/P16 double‐positive breast cancers, and a threefold increase in all‐cause‐related mortality, p53/p16 may be targets for obtaining valid bio‐clinical information for predicting the prognosis of breast cancer patients.192. Here, CDKN2A is linked to breast cancer.